Aardvark Therapeutics, Inc. (AARD) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts AARD Hot Sheet
Join SI Premium – FREE
Aardvark Therapeutics, Inc. (NASDAQ: AARD) reported Q2 EPS of ($0.66), $0.04 better than the analyst estimate of ($0.70).
For earnings history and earnings-related data on Aardvark Therapeutics, Inc. (AARD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ScanSource (SCSC) Misses Q1 EPS by 25c ; Offers Guidance
- MarketWise (MKTW) Tops Q3 EPS by 6c
- Privia Health Group, Inc. (PRVA) Tops Q3 EPS by 12c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
